Info

PhytoCeutica is dedicated to the development of Traditional Chinese Medicine (TCM) into FDA-approved prescription drugs for the treatment of cancer. Utilizing the highest scientific standards to assess safety, efficacy and quality control, PhytoCeutica focuses on relevant preclinical studies, rigorous clinical investigations and a novel platform technology to assess botanical quality control and reproducibility. Chinese medicine has a long, rich and well-respected history with roots that go back thousands of years. Combining this ancient experience-based knowledge with objective, evidence-based scientific studies will engender botanical formulations with a proven, therapeutic utility for treating serious, life-threatening diseases. PhytoCeutica is actively pursuing FDA approval for its lead herbal formulation, PHY906, as a patented broad-spectrum adjuvant with conventional chemotherapy. With compelling pre-clinical studies completed and an advanced quality control platform developed, FDA-allowed Phase I/II clinical studies are currently being conducted. PhytoCeutica is among the leaders in developing high quality botanical medicines of the future. With an experienced management team, board of directors and advisors, PhytoCeutica is pursuing strategic partnerships with Asia, EU and the US to develop an exciting new class of FDA approved prescription medicines.